HAVCR2

Gene

Also known as: TIM-3

Related News

European Biotechs Advance Next-Generation Immunotherapy Targets Beyond PD-1/PD-L1

May 01, 2026

European biotechs are exploring new immunotherapy targets beyond PD-1/PD-L1, including BTLA, TIGIT, and SLAMF6. Lund University researchers discovered a SLAMF6-mediated immune evasion mechanism. BioNTech and GenMab are advancing next-generation ICIs and bispecific antibodies through strategic partnerships.

TET2 Mutations Enhance Cancer Immunotherapy Response in New Studies

Feb 14, 2026

Research shows TET2-driven clonal hematopoiesis improves immune checkpoint blockade efficacy in solid tumors, while separate studies identify new immune pathways in childhood brain cancers and mechanisms behind immunotherapy resistance.